Amgen, Inc., 1120 Veterans Blvd, South San Francisco, CA 94080, USA.
Expert Opin Ther Targets. 2011 Nov;15(11):1307-16. doi: 10.1517/14728222.2011.624514. Epub 2011 Oct 3.
Diabetes and associated metabolic conditions have reached pandemic proportions worldwide and there is a clear unmet medical need for new therapies that are both effective and safe. FGF19 is a distinctive member of the FGF family that functions as an endocrine hormone.
An up-to-date report on the exciting findings related to the involvement of FGF19 in the regulation of glucose, bile acid metabolism and energy expenditure. The role of FGF receptors in these different activities. The therapeutic potential of FGF19 and the engineering opportunities for removing undesirable mitogenic activity.
The ability of FGF19 to regulate bile acid homeostasis, gallbladder filling and tumor development and its potent ability to normalize glucose, lipid and energy homeostasis have made it a potential therapeutic target for the treatment of patients with gallstones, cancer and metabolic diseases, among others. Its potential utility as a novel therapeutic for both type 1 and type 2 diabetes is of particular interest. The ability to separate the undesired mitogenic activity from its potent metabolic activities has opened new opportunities for the development of potential therapeutic molecules based on FGF19 in treating various conditions associated with metabolic syndrome.
糖尿病及相关代谢性疾病在全球范围内已达到流行程度,因此迫切需要新的治疗方法,这些方法不仅有效,而且安全。FGF19 是 FGF 家族的一个独特成员,作为一种内分泌激素发挥作用。
最新报告介绍了 FGF19 参与调节葡萄糖、胆汁酸代谢和能量消耗的令人兴奋的发现。FGF 受体在这些不同活动中的作用。FGF19 的治疗潜力以及去除不良有丝分裂活性的工程机会。
FGF19 调节胆汁酸动态平衡、胆囊充盈和肿瘤发展的能力,以及其有效调节葡萄糖、脂质和能量动态平衡的能力,使其成为治疗胆结石、癌症和代谢性疾病等患者的潜在治疗靶点。其作为新型治疗剂用于 1 型和 2 型糖尿病的潜力尤其引人关注。将其潜在的有丝分裂活性与其有效的代谢活性分离,为基于 FGF19 开发治疗代谢综合征相关各种疾病的潜在治疗分子提供了新的机会。